- PR Newswire•4 hours ago
WESTFORD, Mass., Dec. 5, 2016 /PRNewswire/ -- Cynosure, Inc. (CYNO) today announced it has been recognized as one of Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America. Cynosure received the award for its strong 121% revenue growth between the 2012 and 2015 fiscal years. "Cynosure is honored to be recognized as one of the fastest-growing companies in North America," said Michael Davin, the Company's president and CEO.
- Zacks•5 days ago
Cynosure, Inc. (CYNO) announced that it has received clearance from the China Food and Drug Administration (CFDA) to market the Icon Aesthetic System.
- PR Newswire•6 days ago
WESTFORD, Mass., Nov. 29, 2016 /PRNewswire/ -- Cynosure, Inc. (CYNO) today announced that it has received clearance from the China Food and Drug Administration (CFDA) to market the Icon™ Aesthetic System, the Company's next-generation platform technology for multiple aesthetic indications. With Icon, aesthetic practices in China will be able to deliver the industry's most popular energy-based treatments, including facial vessel and pigment clearance, wrinkle reduction, hair removal and scar and stretch mark treatment, in a single system. "Cynosure was the first U.S. aesthetic laser company to establish a wholly owned subsidiary in China more than 10 years ago, and we continue to expand our competitive position in that country – and the entire Asia Pacific (APAC) region – as part of our international growth strategy," said Michael Davin, the Company's president and CEO.
CYNO : Summary for Cynosure, Inc. - Yahoo Finance
Cynosure, Inc. (CYNO)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||44.25 x 400|
|Ask||44.35 x 300|
|Day's Range||44.25 - 45.20|
|52 Week Range||32.90 - 55.94|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||50.11|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|